Cutaneous Adverse Effects Associated with Iressa(R)(Gefitinib) Medication.
- Author:
Jae Hong PARK
1
;
Jeong Joon OH
;
Yun Lim CHOI
;
Won Serk KIM
;
Joo Heung LEE
;
Eil Soo LEE
Author Information
1. Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. eslee@smc.samsung.co.kr
- Publication Type:Case Report
- Keywords:
Iressa(R)(Gefitinib);
Cutaneous adverse effects;
Acneiform eruption;
Periungal granulation lesion
- MeSH:
Acneiform Eruptions;
Carcinoma, Non-Small-Cell Lung;
Epidermal Growth Factor;
Humans;
Signal Transduction
- From:Korean Journal of Dermatology
2005;43(1):92-95
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We report cutaneous adverse effects developed in three patients and are probably related to Iressa(R)(Gefitinib, ZD1839) medication. Iressa(R) is a new anti-cancer agent which acts by inhibiting epidermal growth factor (EGF) receptor signal transduction. The three patients had all taken Iressa(R) for treatment of non-small cell lung cancer and came to our clinic with cutaneous adverse effects. All three patients had acneiform eruptions, and one of the patients also had periungal granulation lesions. Histopathologically, periadnexal inflammatory cellular infiltrations were seen in the acneiform lesions of the three patients and granulation-like tissue proliferations in periungal granulation lesions of the one patient.
